10-QPeriod: Q3 FY2013

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2013

Filed October 23, 2013For Securities:SYK

Summary

Stryker Corporation's Q3 2013 filing reveals a mixed financial performance. While net sales showed a modest increase of 4.8% year-over-year for the quarter and 3.7% for the nine-month period, driven by volume and acquisitions, net earnings experienced a significant decline of 70.8% in the third quarter and 39.7% for the nine months. This decrease in profitability is largely attributable to substantial charges related to product recalls, specifically the Rejuvenate and ABG II hip stems and the Neptune Waste Management System, as well as increased selling, general, and administrative expenses and restructuring charges. Despite the earnings dip, the company is making strategic moves, including announcing an agreement to acquire MAKO Surgical Corp. for approximately $1.65 billion, signaling a continued focus on robotic-assisted surgery. The company also completed the acquisition of Trauson Holdings Company Limited for $751 million. While liquidity remains strong with substantial cash and equivalents, investors should closely monitor the impact of ongoing legal and regulatory matters, particularly the potential liabilities from the hip stem recall, which could significantly influence future financial results.

Financial Highlights

50 data points
Beta

Revenue

$2.15B

68.3% Gross Margin

Net Income

$103.00M

4.8% Net Margin

EPS (Diluted)

$0.27

Total Assets

$14.88B

Cash & Equivalents

$1.11B

Free Cash Flow

$579.00M

Financial Statements
Beta
Revenue$2.15B
Cost of Revenue$682.00M
Gross Profit$1.47B
R&D Expenses$136.00M
SG&A Expenses$1.14B
Operating Expenses$1.32B
Operating Income$150.00M
Net Income$103.00M
EPS (Basic)$0.27
EPS (Diluted)$0.27
Shares Outstanding (Basic)378.30M
Shares Outstanding (Diluted)381.70M

Key Highlights

  • 1Net sales increased by 4.8% to $2.15 billion for the three months ended September 30, 2013, and by 3.7% to $6.55 billion for the nine months ended September 30, 2013, compared to the prior year periods.
  • 2Net earnings significantly decreased by 70.8% to $103 million for the three months ended September 30, 2013, and by 39.7% to $620 million for the nine months ended September 30, 2013.
  • 3Diluted Earnings Per Share (EPS) saw a substantial decline, falling to $0.27 for the three months and $1.62 for the nine months, down from $0.92 and $2.68 respectively in the prior year periods.
  • 4The company announced an agreement to acquire MAKO Surgical Corp. for approximately $1.65 billion, underscoring a strategic push into robotic-assisted surgery.
  • 5Significant charges were incurred due to the voluntary recall of Rejuvenate and ABG II hip stems and the Neptune Waste Management System, impacting profitability.
  • 6Selling, General, and Administrative (SG&A) expenses increased substantially by 43.6% for the quarter and 26.1% for the nine months, largely due to recall-related expenses and other charges.
  • 7Cash from operations remained strong, increasing to $622 million for the three months and $1,214 million for the nine months, demonstrating resilient operational cash generation despite the earnings decline.

Frequently Asked Questions

The substantial decrease in net earnings is primarily driven by significant charges related to the voluntary recall of the Rejuvenate and ABG II modular-neck hip stems and the Neptune Waste Management System. Additionally, increased selling, general, and administrative expenses, including acquisition and integration costs, and restructuring charges also contributed to the decline in profitability.

The announced acquisition of MAKO Surgical Corp. for approximately $1.65 billion signals Stryker's strategic intent to bolster its position in the rapidly growing field of robotic-assisted surgery. This move is expected to enhance Stryker's capabilities in joint reconstruction and surgical technology, potentially driving future growth and innovation.

Stryker continues to maintain strong liquidity. Cash from operations remained robust, increasing for both the three-month and nine-month periods. The company also has significant cash, cash equivalents, and marketable securities on hand. The issuance of new debt in March 2013, along with available credit facilities, provides further flexibility for funding operations, potential acquisitions, and stock repurchases.

Key risks include the ongoing legal and regulatory matters, particularly the substantial potential liabilities associated with the hip stem recall, which has an estimated probable loss range of $700 to $1,130 million before insurance recoveries. The outcomes of these matters are difficult to predict and could materially affect financial position, results of operations, and cash flows. Additionally, unfavorable pricing pressures and foreign currency exchange rate fluctuations, particularly in certain international markets, could continue to impact sales growth.